PE20030760A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents

Moleculas pequenas para el tratamiento del crecimiento celular anormal

Info

Publication number
PE20030760A1
PE20030760A1 PE2002001190A PE2002001190A PE20030760A1 PE 20030760 A1 PE20030760 A1 PE 20030760A1 PE 2002001190 A PE2002001190 A PE 2002001190A PE 2002001190 A PE2002001190 A PE 2002001190A PE 20030760 A1 PE20030760 A1 PE 20030760A1
Authority
PE
Peru
Prior art keywords
treatment
cellular growth
erbb2
methyl
abnormal cellular
Prior art date
Application number
PE2002001190A
Other languages
English (en)
Inventor
Richard Damian Connell
James Dale Moyer
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030760A1 publication Critical patent/PE20030760A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN INHIBIDOR DE erbB2 DE MOLECULA PEQUENA QUE PRESENTA UN INTERVALO DE SELECTIVIDAD POR erbB2 RESPECTO A erbB1 ENTRE 50-1500 Y UNA CI50 MENOR A 50nM. EL INHIBIDOR DE erbB2 SE SELECCIONA DE N-{3-[4-(5-METIL-6-FENOXIPIRIDIN-3-ILAMINO)-QUINAZOLIN-6-IL]-PROP-2-INIL}-2-OXO-PROPIONAMIDA, (3-4{4-[3-METIL-4-(PIRIDIN-3-ILOXI)-FENILAMINO]-QUINAZOLIN-6-IL]-AMINA DEL ACIDO CICLOPROPANOCARBOXILICO, 2-METOXI-N-(3-{4-(4-(3-METOXIFENOXI)-3-METIL-FENILAMINO)-QUINAZOLIN-6-IL}-PROP-2-INIL)-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL
PE2002001190A 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal PE20030760A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
PE20030760A1 true PE20030760A1 (es) 2003-09-05

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001190A PE20030760A1 (es) 2001-12-12 2002-12-10 Moleculas pequenas para el tratamiento del crecimiento celular anormal

Country Status (29)

Country Link
US (1) US20030171386A1 (es)
EP (1) EP1465632A1 (es)
JP (1) JP4181502B2 (es)
KR (1) KR20040063948A (es)
CN (1) CN1602195A (es)
AP (1) AP2004003058A0 (es)
AR (1) AR037771A1 (es)
AU (1) AU2002339687A1 (es)
BR (1) BR0214499A (es)
CA (1) CA2469670A1 (es)
DO (1) DOP2002000545A (es)
EA (1) EA200400680A1 (es)
EC (1) ECSP045146A (es)
GT (1) GT200200273A (es)
HR (1) HRP20040529A2 (es)
HU (1) HUP0501069A2 (es)
IL (1) IL161908A0 (es)
IS (1) IS7233A (es)
MA (1) MA27154A1 (es)
MX (1) MXPA04004107A (es)
NO (1) NO20042882L (es)
OA (1) OA12734A (es)
PA (1) PA8561301A1 (es)
PE (1) PE20030760A1 (es)
PL (1) PL373848A1 (es)
TN (1) TNSN04111A1 (es)
TW (1) TW200301121A (es)
WO (1) WO2003049740A1 (es)
ZA (1) ZA200404264B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4703183B2 (ja) * 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
JP2006513179A (ja) * 2002-12-18 2006-04-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のための４−アニリノキナゾリン誘導体
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
CA2536140A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
PL2213661T3 (pl) 2003-09-26 2011-12-30 Exelixis Inc Modulatory c-Met i sposoby ich zastosowania
EP1708712A1 (en) * 2003-12-24 2006-10-11 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
NZ550796A (en) * 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
MY150290A (en) 2008-02-07 2013-12-31 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
WO2010015522A1 (de) 2008-08-08 2010-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5677318B2 (ja) 2009-01-16 2015-02-25 エクセリクシス， インク． Ｎ−（４−｛［６，７−ビス（メチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドのリンゴ酸塩およびその結晶質形態
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US20130084286A1 (en) 2011-08-31 2013-04-04 Thomas E. Januario Diagnostic markers
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
CN107922609B (zh) 2015-07-01 2020-04-24 加州理工学院 基于阳离子粘酸聚合物的递送系统
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
JP2023512175A (ja) * 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
US20230126204A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1192151B1 (en) * 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
SK286628B6 (sk) * 1999-10-19 2009-02-05 Merck & Co., Inc. Inhibítory tyrozín-kinázy, farmaceutický prostriedok s ich obsahom a ich použitie
EA005525B1 (ru) * 2000-06-22 2005-04-28 Пфайзер Продактс Инк. Замещенные бициклические производные для лечения аномального роста клеток
MXPA04005678A (es) * 2001-12-12 2004-12-06 Pfizer Prod Inc Formas de sal de e-2 -metoxi -n- (3- (4- (3-metil -piridin-3- iloxil ) fenilamino) quinazolin -6-il) alil) alil) acetamida, su preparacion y su uso contra el cancer.

Also Published As

Publication number Publication date
ECSP045146A (es) 2004-07-23
EA200400680A1 (ru) 2005-06-30
PL373848A1 (en) 2005-09-19
US20030171386A1 (en) 2003-09-11
BR0214499A (pt) 2005-05-10
GT200200273A (es) 2003-10-03
KR20040063948A (ko) 2004-07-14
OA12734A (en) 2006-06-28
AU2002339687A1 (en) 2003-06-23
IL161908A0 (en) 2005-11-20
AP2004003058A0 (en) 2004-06-30
IS7233A (is) 2004-04-26
TNSN04111A1 (fr) 2006-06-01
CN1602195A (zh) 2005-03-30
TW200301121A (en) 2003-07-01
HUP0501069A2 (en) 2006-06-28
AR037771A1 (es) 2004-12-01
CA2469670A1 (en) 2003-06-19
EP1465632A1 (en) 2004-10-13
MXPA04004107A (es) 2004-07-23
JP4181502B2 (ja) 2008-11-19
HRP20040529A2 (en) 2004-10-31
MA27154A1 (fr) 2005-01-03
ZA200404264B (en) 2005-08-31
WO2003049740A1 (en) 2003-06-19
PA8561301A1 (es) 2003-12-30
DOP2002000545A (es) 2003-06-16
NO20042882L (no) 2004-07-07
JP2005527486A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
PE20030760A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
PE20050598A1 (es) Compuestos moduladores de cb1
PE20050229A1 (es) Derivados de etinilprolina
ME00353B (me) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
PE20091901A1 (es) Activadores de glucoquinasa
MX2007005408A (es) Compuestos de aminoquinazolinas.
PE20211375A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
HRP20050352B1 (hr) Piperazinilni i diazepanilni benzamidi i benztioamidi
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
UY26291A1 (es) Compuestos químicos xxii
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
PE20110581A1 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
CO5700779A2 (es) Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas
PE20050342A1 (es) Tableta que contiene el ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico o sus sales
PE20010913A1 (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas
TR200403020T2 (tr) (S)-4-Amino-5-kloro-2-metoksi-N- (1-(1-(2-tetrahidrofuril-carbonil)-4-piperidinylmetil) -4-piperidinil)benzamit, bunun hazırlama işlemi ve aynı formülü ve bunun ara mamülünü içeren farmasötik bileşim
MA32818B1 (fr) Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb
PE20061363A1 (es) Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina como agonistas del receptor fsh

Legal Events

Date Code Title Description
FC Refusal